A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
Tak Yun, Heung Tae Kim, Ji-Youn Han, Sung Jin Yoon, Hyae Young Kim, Byung-Ho Nam, Jin Soo Lee
Cancer Res Treat. 2016;48(2):465-472.   Published online 2015 May 26     DOI: https://doi.org/10.4143/crt.2015.061
Citations to this article as recorded by Crossref logo
Combination therapy with carboplatin and paclitaxel for small cell lung cancer
Atsuto Mouri, Ou Yamaguchi, Sachiko Miyauchi, Ayako Shiono, Harue Utsugi, Fuyumi Nishihara, Yoshitake Murayama, Hiroshi Kagamu, Kunihiko Kobayashi
Respiratory Investigation.2019; 57(1): 34.     CrossRef
Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens
Yuji Takei, Yoshifumi Takahashi, Shizuo Machida, Akiyo Taneichi, Suzuyo Takahashi, Tomomi Nagashima, Hiroyuki Morisawa, Yasushi Saga, Shigeki Matsubara, Hiroyuki Fujiwara
Journal of Obstetrics and Gynaecology Research.2017; 43(2): 358.     CrossRef
Second-line treatments of small-cell lung cancers
Nathalie Baize, Isabelle Monnet, Laurent Greillier, Gilles Quere, Mallorie Kerjouan, Henri Janicot, Alain Vergnenegre, Jean Bernard Auliac, Christos Chouaid
Expert Review of Anticancer Therapy.2017; 17(11): 1033.     CrossRef